TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32594244

Group type: EXPERIMENTAL
Intervention: Primed ramp test
Number of subjects: 21

Group type: COMPARATOR
Intervention: Unprimed ramp test
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both ramp tests
Number of subjects: 21
Study: 34949526

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 95
Study: 34283893

Group type: EXPERIMENTAL
Intervention: Tailored messaging (TM+)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Targeted messaging (TM)
Number of subjects: 149
Study: 32105790

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 74
Study: 35893914

Group type: EXPERIMENTAL
Intervention: Oligomeric hyperproteic normocaloric (OHN) supplement
Number of subjects: 151

Group type: COMPARATOR
Intervention: Immunonutritional (IN) supplement
Number of subjects: 151
Study: 35791877

Group type: EXPERIMENTAL
Intervention: 6 mg/kg of caffeine during baseline night (BN)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 2 mg/kg of caffeine during total sleep deprivation (TSD)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 6 mg/kg of caffeine during BN
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 2 mg/kg of caffeine during TSD
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo during BN
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo during TSD
Number of subjects: 12
Study: 34116206

Group type: EXPERIMENTAL
Intervention: Positively Smoke Free Video-Groups
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy Relationship Video-Groups (Control)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both groups (Positively Smoke Free and Healthy Relationship)
Number of subjects: 0
Study: 33072373

Group type: EXPERIMENTAL
Intervention: Individual nutritional counselling and physical activity training
Number of subjects: 66
Study: 35015903

Group type: EXPERIMENTAL
Intervention: Subcutaneous methotrexate (MTX)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Oral methotrexate (MTX)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 77
Study: 33499510

Group type: EXPERIMENTAL
Intervention: CBTIweb.org
Number of subjects: 41

Group type: COMPARATOR
Intervention: In-person workshop
Number of subjects: 41
Study: 34320100

Group type: EXPERIMENTAL
Intervention: Phakic patients
Number of subjects: 40

Group type: COMPARATOR
Intervention: Pseudophakic patients
Number of subjects: 40
Study: 32679400

Group type: EXPERIMENTAL
Intervention: Healthcare service use (hospitalisations, mental health and regular emergency department visits, outpatient visits)
Number of subjects: 671

Group type: EXPERIMENTAL
Intervention: Emergency department visits
Number of subjects: 671

Group type: EXPERIMENTAL
Intervention: Financial barriers (resources and health insurance)
Number of subjects: 671

Group type: EXPERIMENTAL
Intervention: Social functioning score
Number of subjects: 671

Group type: EXPERIMENTAL
Intervention: Diagnosis of schizophrenia
Number of subjects: 671

Group type: EXPERIMENTAL
Intervention: Mental health scores (Medical Outcomes Study 36-item Short Form Health Survey)
Number of subjects: 671

Group type: EXPERIMENTAL
Intervention: Alcohol dependence
Number of subjects: 671

Group type: EXPERIMENTAL
Intervention: Being ‘absolutely homeless’
Number of subjects: 671

Group type: EXPERIMENTAL
Intervention: Homelessness trajectory factors
Number of subjects: 671
Study: 36404301

Group type: EXPERIMENTAL
Intervention: Erenumab 70 mg
Number of subjects: 557

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 557
Study: 35803643

Group type: EXPERIMENTAL
Intervention: Art-based intervention with five visual thinking activities
Number of subjects: 94
Study: 34671412

Group type: EXPERIMENTAL
Intervention: ImmuActive
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 35165769

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided genicular nerve block (GNB)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Physical therapy (PT)
Number of subjects: 102
Study: 32898578

Group type: EXPERIMENTAL
Intervention: Family Integrated Care (FICare)
Number of subjects: 601

Group type: COMPARATOR
Intervention: Standard Care (Control)
Number of subjects: 601
Study: 33187677

Group type: EXPERIMENTAL
Intervention: Synthetic Surfactant CHF5633
Number of subjects: 0

Group type: COMPARATOR
Intervention: Poractant Alfa
Number of subjects: 0
Study: 35836924

Group type: EXPERIMENTAL
Intervention: 5E rehabilitation nursing model
Number of subjects: 60
Study: 34456042

Group type: EXPERIMENTAL
Intervention: Real SNAG group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham SNAG group
Number of subjects: 30
Study: 33664449

Group type: EXPERIMENTAL
Intervention: Eosinophil count
Number of subjects: 173480

Group type: EXPERIMENTAL
Intervention: Eosinophil percentage of white cells
Number of subjects: 173480

Group type: COMPARATOR
Intervention: HBC traits
Number of subjects: 173480
Study: 32078436

Group type: EXPERIMENTAL
Intervention: Cocoa beverage (15 g of cocoa and 75 mg of epicatechin daily)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo beverage (identical appearance, contained neither cocoa nor epicatechin)
Number of subjects: 44
Study: 36194164

Group type: EXPERIMENTAL
Intervention: Everolimus (10 mg, oral daily for a maximum of 1 year)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 33983634

Group type: EXPERIMENTAL
Intervention: Training group receiving six supervised functional training sessions of 10 min each
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group without training
Number of subjects: 20
Study: 32167494

Group type: EXPERIMENTAL
Intervention: Femoral central venous catheter insertion site
Number of subjects: 7235

Group type: EXPERIMENTAL
Intervention: Femoral arterial catheter insertion site
Number of subjects: 7235

Group type: COMPARATOR
Intervention: Nonfemoral central venous catheter insertion site
Number of subjects: 7235

Group type: COMPARATOR
Intervention: Nonfemoral arterial catheter insertion site
Number of subjects: 7235
Study: 35704561

Group type: EXPERIMENTAL
Intervention: Dog-assisted interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Relaxation intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment control group
Number of subjects: 0
Study: 33038018

Group type: EXPERIMENTAL
Intervention: High-load RT to failure (HLF, n = 11, 75% of 1RM, three sets to failure)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: High-load RT without failure (HLNF, n = 11, 75% of 1RM, six sets of five repetitions)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Low-load RT to failure (LLF, n = 11, 25% of 1RM, three sets to failure)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (CON, n = 9)
Number of subjects: 42
Study: 33351127

Group type: EXPERIMENTAL
Intervention: melphalan-prednisone-lenalidomide followed by lenalidomide maintenance (MPR-R)
Number of subjects: 168

Group type: COMPARATOR
Intervention: melphalan-prednisone-thalidomide followed by thalidomide maintenance (MPT-T)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: SKY-RISS I (SKY-SR 1 R-ISS-I)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: SKY-RISS II (all other patients)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: SKY-RISS III (SKY-HR 1 R-ISS-II/III)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: SKY92 classifier
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: R-ISS
Number of subjects: 168
Study: 36271422

Group type: EXPERIMENTAL
Intervention: Improved housing modifications as part of the RooPfs trial
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Local perceptions of a good house
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Long-term relationship with the implementing institution
Number of subjects: 391
Study: 33812488

Group type: EXPERIMENTAL
Intervention: Delayed strategy (RRT started just after randomisation)
Number of subjects: 278

Group type: COMPARATOR
Intervention: More-delayed strategy (RRT initiation postponed until mandatory indication or blood urea nitrogen concentration reached 140 mg/dL)
Number of subjects: 278

Group type: COMPARATOR
Intervention: More-delayed strategy
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Both strategies
Number of subjects: 278
Study: 34980050

Group type: EXPERIMENTAL
Intervention: Prone position lumbar puncture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lateral decubitus position lumbar puncture
Number of subjects: 0
Study: 34326178

Group type: EXPERIMENTAL
Intervention: Home visiting intervention (32.7 visits by family midwives and/or social pedagogues until child age 2 years)
Number of subjects: 755
Study: 32671719

Group type: EXPERIMENTAL
Intervention: Cabozantinib (Cabometyx®)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35319832

Group type: EXPERIMENTAL
Intervention: Chitogel
Number of subjects: 25
Study: 36116104

Group type: EXPERIMENTAL
Intervention: Couple HOPES (online couple intervention for PTSD)
Number of subjects: 27
Study: 33568230

Group type: EXPERIMENTAL
Intervention: Locally applied gentamicin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 0
Study: 33285624

Group type: EXPERIMENTAL
Intervention: Focused shock wave therapy (FSWT)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Radial shock wave therapy (RSWT)
Number of subjects: 55
Study: 35999526

Group type: EXPERIMENTAL
Intervention: PVP + FB (Group PF)
Number of subjects: 198

Group type: COMPARATOR
Intervention: PVP (Group P)
Number of subjects: 198
Study: 34912505

Group type: EXPERIMENTAL
Intervention: Systematic corrective exercises for 12 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Routine exercise (control group)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Static balance (Flamingo balance test)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Static balance (stabilometr)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dynamic balance (star excursion balance test - anterior direction)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dynamic balance (star excursion balance test - posterior-internal direction)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dynamic balance (star excursion balance test - posterior-external direction)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dynamic balance (stabilometr)
Number of subjects: 30
Study: 33272026

Group type: EXPERIMENTAL
Intervention: Community-based self-management intervention
Number of subjects: 500
Study: 32451161

Group type: EXPERIMENTAL
Intervention: Physical therapist‐led exercise and education program for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Minimal intervention
Number of subjects: 0
Study: 35379064

Group type: EXPERIMENTAL
Intervention: Ticagrelor (90 mg twice daily for 2 weeks)
Number of subjects: 50
Study: 34107836

Group type: EXPERIMENTAL
Intervention: 5C1E (5s concentric action and 1s eccentric action)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 3C3E (3s concentric action and 3s eccentric action)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 1C5E (1s concentric action and 5s eccentric action)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 32196749

Group type: EXPERIMENTAL
Intervention: ABP 959 (300 mg IV infusion)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Eculizumab US (FDA-licensed)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Eculizumab EU (EU-authorized)
Number of subjects: 0
Study: 33128537

Group type: EXPERIMENTAL
Intervention: Expert consensus on diagnostic standard and syndrome types for palpitations below the heart.
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Main diagnoses identified in TCM for palpitations below the heart.
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Secondary diagnosis identified in TCM for palpitations below the heart.
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: TCM syndrome differentiation for palpitations below the heart.
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Reliability of expert opinions in the consultation process.
Number of subjects: 19
Study: 32496922

Group type: EXPERIMENTAL
Intervention: 3D‐printed PCNL model (Group B)
Number of subjects: 40

Group type: COMPARATOR
Intervention: URO Mentor™ surgical simulator (Group A)
Number of subjects: 40
Study: 35400328

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan (97/103 mg once or twice daily)
Number of subjects: 502

Group type: COMPARATOR
Intervention: Telmisartan (40 mg once or twice daily)
Number of subjects: 502
Study: 34144432

Group type: EXPERIMENTAL
Intervention: Parenting training intervention
Number of subjects: 280
Study: 32406858

Group type: EXPERIMENTAL
Intervention: Web-based self-management intervention
Number of subjects: 1193

Group type: COMPARATOR
Intervention: Paper-based observational follow-up study
Number of subjects: 1193
Study: 35088556

Group type: COMPARATOR
Intervention: Laparoscopic Roux-en-Y gastric bypass (LRYGB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Responsive deep brain stimulation (rDBS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness threshold for rDBS
Number of subjects: 0
Study: 33038096

Group type: EXPERIMENTAL
Intervention: Nutritional intervention (polyphenols, omega-3, vitamin E, selenium)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal diet (control)
Number of subjects: 20
Study: 35614523

Group type: EXPERIMENTAL
Intervention: Smoking cessation intervention for dual users of combustible and electronic cigarettes
Number of subjects: 2706
Study: 33509129

Group type: EXPERIMENTAL
Intervention: Oral dydrogesterone (10 mg three times per day)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 32744483

Group type: EXPERIMENTAL
Intervention: Audio-recorded hypnosis intervention
Number of subjects: 97

Group type: COMPARATOR
Intervention: Standard pharmacological treatment and usual physical or psychological activities
Number of subjects: 97
Study: 35065003

Group type: EXPERIMENTAL
Intervention: Cryoablation
Number of subjects: 223

Group type: COMPARATOR
Intervention: RFA
Number of subjects: 223
Study: 33387931

Group type: EXPERIMENTAL
Intervention: Reverse Valsalva manoeuvre
Number of subjects: 11

Group type: COMPARATOR
Intervention: Modified Valsalva manoeuvre
Number of subjects: 11
Study: 35363345

Group type: EXPERIMENTAL
Intervention: Trampoline-based stretch-shortening cycle (SSC) exercises
Number of subjects: 32
Study: 36172511

Group type: EXPERIMENTAL
Intervention: PEERS training program
Number of subjects: 0
Study: 35870990

Group type: EXPERIMENTAL
Intervention: S(+)‐ketamine hydrochloride injection
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Conventional therapy without S(+)‐ketamine
Number of subjects: 3000
Study: 33783089

Group type: EXPERIMENTAL
Intervention: Frankfort Mandibular Plane Angle (FMA) as a diagnostic test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical trials related to FMA
Number of subjects: 0
Study: 32700393

Group type: EXPERIMENTAL
Intervention: Ertugliflozin (5 or 15 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35460601

Group type: EXPERIMENTAL
Intervention: Dolutegravir (50 mg once daily)
Number of subjects: 464

Group type: COMPARATOR
Intervention: Ritonavir-boosted darunavir (800 mg of darunavir plus 100 mg of ritonavir once daily)
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Tenofovir (300 mg once daily) plus lamivudine (300 mg once daily)
Number of subjects: 464

Group type: COMPARATOR
Intervention: Zidovudine (300 mg twice daily) plus lamivudine (150 mg twice daily)
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 464
Study: 32950597

Group type: EXPERIMENTAL
Intervention: Lugol-unstained lesions (LULs) size >5 mm
Number of subjects: 1058

Group type: COMPARATOR
Intervention: Lugol-unstained lesions (LULs) size ≤5 mm
Number of subjects: 1058

Group type: EXPERIMENTAL
Intervention: Modified surveillance strategy for individuals with medium (6-10 mm) and large (>10 mm) nondysplastic LULs
Number of subjects: 1058
Study: 32756135

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock-wave therapy (ESWT) - 3 sessions on the first, 14th, and 28th days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral prednisolone - 30 mg daily for 2 weeks, then 15 mg daily for another 2 weeks
Number of subjects: 0
Study: 35604613

Group type: EXPERIMENTAL
Intervention: Bilateral erector spinae plane block using 20 ml of 0.375% ropivacaine on each side (ESPB group, n = 42)
Number of subjects: 84

Group type: COMPARATOR
Intervention: No block (control group, n = 42)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Bilateral erector spinae plane block
Number of subjects: 84
Study: 32331018

Group type: EXPERIMENTAL
Intervention: Valbenazine 40 mg
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Valbenazine 80 mg
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Valbenazine (40 or 80 mg)
Number of subjects: 143
Study: 35296478

Group type: EXPERIMENTAL
Intervention: I-WOTCH intervention (multicomponent self-management support package)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: I-WOTCH intervention
Number of subjects: 0
Study: 34320575

Group type: EXPERIMENTAL
Intervention: Surgical mandibular advancement (Group SG)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Premolar extractions (Group CG)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 46
Study: 34148136

Group type: EXPERIMENTAL
Intervention: CFs‐SVM classifier integrating collagen area, straightness, and crosslink density
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: CFs nomogram integrating CFs‐SVM classifier and clinicopathological characteristics
Number of subjects: 428

Group type: COMPARATOR
Intervention: Traditional clinicopathological model
Number of subjects: 428
Study: 33747831

Group type: EXPERIMENTAL
Intervention: Digital educational support group administered through WhatsApp Messenger
Number of subjects: 58
Study: 33768777

Group type: EXPERIMENTAL
Intervention: Kinesio taping of the knee
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no Kinesio taping)
Number of subjects: 31
Study: 33201347

Group type: EXPERIMENTAL
Intervention: Fluconazole 400 mg daily for 8 days
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 33533164

Group type: EXPERIMENTAL
Intervention: Neck-specific exercises
Number of subjects: 144

Group type: COMPARATOR
Intervention: General exercises
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Anxiety at 3rd month
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Head pain at 3rd month
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Self-efficacy
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Neck–arm pain
Number of subjects: 144
Study: 35821379

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Sleep Duration
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Sleep Efficiency
Number of subjects: 29
Study: 32830127

Group type: EXPERIMENTAL
Intervention: 360° incision
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: upper-180° incision
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: lower-180° incision
Number of subjects: 99
Study: 35218405

Group type: EXPERIMENTAL
Intervention: 16 mg BUP (BUP16)
Number of subjects: 302
Study: 34762980

Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) for 4 weeks
Number of subjects: 70

Group type: COMPARATOR
Intervention: Sham group (SG)
Number of subjects: 70
Study: 33232628

Group type: COMPARATOR
Intervention: Group A: no planned follow-up contact
Number of subjects: 487

Group type: COMPARATOR
Intervention: Group B: a single, planned, structured follow-up telephone contact with the research nurse the day after discharge
Number of subjects: 487

Group type: COMPARATOR
Intervention: Group C: planned, structured follow-up telephone contact with the research nurse the day after discharge and then once weekly for 6 weeks
Number of subjects: 487

Group type: COMPARATOR
Intervention: Group D: as Group C, but with planned, structured, coaching telephone contact
Number of subjects: 487
Study: 32066625

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MedDiet) intervention for 12 months
Number of subjects: 612
Study: 33271458

Group type: EXPERIMENTAL
Intervention: Resin composites (six different classifications and viscosities)
Number of subjects: 76
Study: 32611505

Group type: EXPERIMENTAL
Intervention: Afatinib (30 mg or 40 mg orally daily)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Chemotherapy (pemetrexed 500 mg/m2 + cisplatin 75 mg/m2 or carboplatin AUC 5 or 6 every 3 weeks × 4 cycles, followed by pemetrexed 500 mg/m2 every 3 weeks)
Number of subjects: 106
Study: 35090173

Group type: EXPERIMENTAL
Intervention: 8 h Nap schedule (6.5 h nocturnal sleep with a 90‐minute daytime nap)
Number of subjects: 53

Group type: COMPARATOR
Intervention: 8 h No‐Nap, nocturnal‐only sleep schedule
Number of subjects: 53
Study: 33258136

Group type: EXPERIMENTAL
Intervention: Immediate loading group
Number of subjects: 158

Group type: COMPARATOR
Intervention: Delayed loading group
Number of subjects: 158
Study: 35410927

Group type: EXPERIMENTAL
Intervention: Cognitive training with anodal tDCS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cognitive training with sham tDCS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Defined muscle relaxation training with sham tDCS
Number of subjects: 0
Study: 33530006

Group type: EXPERIMENTAL
Intervention: Usual care plus a brief educational video on safe storage and disposal practices of unused opioid pills
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 40
Study: 32937035

Group type: EXPERIMENTAL
Intervention: Revised participant tracking system and retraining of sites regarding study procedures
Number of subjects: 997

Group type: EXPERIMENTAL
Intervention: Comprehensive audit of enrollment forms
Number of subjects: 997
Study: 35897080

Group type: EXPERIMENTAL
Intervention: Social incentives with gamification to promote exercise
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Corticosteroid injections
Number of subjects: 220

Group type: COMPARATOR
Intervention: Lidocaine-only injection
Number of subjects: 220

Group type: COMPARATOR
Intervention: Fitbit without incentives
Number of subjects: 220